Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GeNeuro

Biogen Idec building

New intramuscular administration for Biogen’s MS therapy Plegridy approved in the EU

New administration offers same efficacy as subcutaneous injection

- PMLiVE

Servier to acquire Agios’ oncology business in $1.8bn deal

French pharma will also gain Agios' oncology-associated employees

- PMLiVE

Novartis’ MS therapy Mayzent approved by NICE

Agency approves drug after new cost-effectiveness proposal

- PMLiVE

Amgen, Cytokinetics’ heart failure drug disappoints in phase 3

Drug hit primary endpoint but missed secondary endpoint of reduction in cardiovascular death

- PMLiVE

Roche’s Ocrevus boasts positive long-term data in MS

After two years of treatment 75% of patients had no evidence of disease activity

- PMLiVE

Novartis wins FDA approval for relapsing MS drug Kesimpta

Swiss pharma company is expecting EU approval for treatment next year

Sanofi reception

Sanofi bolsters pipeline with $3.7bn deal for Principia Biopharma

French drugmaker will gain access to a portfolio of BTK inhibitors

- PMLiVE

Novartis builds its case for novel MS treatment ofatumumab

Detailed results from phase 3 studies published in NEJM

- PMLiVE

Trial of Amgen, Servier’s heart failure drug clears interim check

Drug could become a $2bn product if approved

What gets on your nerves?

COUCH Health

- PMLiVE

Servier and Oncodesign reach first milestone in Parkinson’s partnership

Oncodesign receives first success payment of €1m

- PMLiVE

Biogen triumphs over Mylan’s Tecfidera patent challenge

Shares in Biogen skyrocketed by 32% following ruling

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links